HC Wainwright Forecasts Pharming Group Q3 Earnings

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Investment analysts at HC Wainwright issued their Q3 2026 EPS estimates for Pharming Group in a research report issued on Thursday, March 12th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of $0.12 per share for the quarter. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Pharming Group’s FY2027 earnings at $0.69 EPS.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, March 12th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.08). The business had revenue of $106.50 million for the quarter, compared to analyst estimates of $111.76 million. Pharming Group had a return on equity of 1.08% and a net margin of 0.71%.

PHAR has been the topic of a number of other research reports. Wall Street Zen raised Pharming Group to a “strong-buy” rating in a report on Saturday, December 27th. Oppenheimer reaffirmed an “outperform” rating and set a $41.00 price target (down from $42.00) on shares of Pharming Group in a report on Friday, March 13th. Weiss Ratings lowered shares of Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. Finally, Zacks Research cut shares of Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Two investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Pharming Group currently has an average rating of “Hold” and a consensus price target of $39.00.

Pharming Group Stock Up 0.4%

PHAR opened at $15.49 on Monday. Pharming Group has a 52 week low of $7.50 and a 52 week high of $21.34. The business has a 50 day moving average price of $17.15 and a two-hundred day moving average price of $16.10. The company has a quick ratio of 2.03, a current ratio of 2.59 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.09 billion, a PE ratio of 1,549.00 and a beta of 0.04.

Institutional Investors Weigh In On Pharming Group

Large investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC bought a new stake in shares of Pharming Group during the second quarter valued at approximately $32,000. SmartHarvest Portfolios LLC bought a new position in Pharming Group in the 4th quarter worth approximately $224,000. Millennium Management LLC acquired a new stake in Pharming Group in the 4th quarter valued at approximately $360,000. Finally, NewEdge Advisors LLC increased its position in Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after acquiring an additional 28,615 shares during the period. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.